Skip to main content

ESTUDIO DE LOS MECANISMOS MOLECULARES DE LA SINAPSIS IMPLICADOS EN PROCESOS COGNITIVOS Y EN LA DISCAPACIDAD COGNITIVA NO SINDROMICA

BFU2012-34398

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2012
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Secretaría de Estado de Investigación, Desarrollo e Innovación
Beneficiary centre INSTITUT DE RECERCA DE L HOSPITAL DE LA SANTA CREU I SANT PAU

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer's disease cerebrospinal fluid

  • Lleó, Alberto
  • Chiva, Cristina
  • Sabidó Aguadé, Eduard, 1981-
  • Belbin, Olivia
A biomarker of synapse loss, an early event in Alzheimer's disease (AD) pathophysiology that precedes neuronal death and symptom onset, would be a much-needed prognostic biomarker. With direct access to the brain interstitial fluid, the cerebrospinal fluid (CSF) is a potential source of synapse-derived proteins. In this study, we aimed to identify and validate novel CSF biomarkers of synapse loss in AD. Discovery: Combining shotgun proteomics of the CSF with an exhaustive search of the literature and public databases, we identified 251 synaptic proteins, from which we selected 22 for further study. Verification: Twelve proteins were discarded because of poor detection by Selected Reaction Monitoring (SRM). We confirmed the specific expression of 9 of the remaining proteins (Calsynytenin-1, GluR2, GluR4, Neurexin-2A, Neurexin-3A, Neuroligin-2, Syntaxin-1B, Thy-1, Vamp-2) at the human synapse using Array Tomography microscopy and biochemical fractionation methods. Exploration: Using SRM, we monitored these 9 synaptic proteins (20 peptides) in a cohort of CSF from cognitively normal controls and subjects in the pre-clinical and clinical AD stages (n = 80). Compared with controls, peptides from 8 proteins were elevated 1.3 to 1.6-fold (p < 0.04) in prodromal AD patients. Validation: Elevated levels of a GluR4 peptide at the prodromal stage were replicated (1.3-fold, p = 0.04) in an independent cohort (n = 60). Moreover, 7 proteins were reduced at preclinical stage 1 (0.6 to 0.8-fold, p < 0.04), a finding that was replicated (0.7 to 0.8-fold, p < 0.05) for 6 proteins in a third cohort (n = 38). In a cross-cohort meta-analysis, 6 synaptic proteins (Calsyntenin-1, GluR4, Neurexin-2A, Neurexin-3A, Syntaxin-1B and Thy-1) were reduced 0.8-fold (p < 0.05) in preclinical AD, changes that precede clinical symptoms and CSF markers of neurodegeneration. Therefore, these proteins could have clinical value for assessing disease progression, especially in preclinical stages of AD., This work was supported by the following research grants: Fondos de Investigaciones Sanitarias (PI15/00058, PI14/01561, PI18/000327) from the “Fondo Europeo de Desarrollo Regional (FEDER)”, Unión Europea, “Una manera de hacer Europa” and the “Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Gobierno de España” (ISCIII). Additional funding came from the “Departament de Salut, Generalitat de Cataluña - Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016 –2020, 2017–2019” (SLT002/16/00408, 2017SGR547), “Programa 1 Enfermedad de Alzheimer y otras demencias degenerativas” from the Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), the “Fundació Bancaria La Caixa” (4560/6393) and “La Marató” organized by the television channel, TV3 (20142610). OB is supported by the Miguel Servet program (CP13/00091) from the ISCIII and FEDER. AB is supported by the Ministerio de Economia y Competitividad, Gobierno de España and FEDER (BFU2012-34398 and BFU2015-69717-P), by the Career Integration Grant from the European Union (ref. 304111, Marie Curie Actions), by the Ramón y Cajal Fellowship (ref. RYC-2011-08391) from the Ministerio de Economia y Competitividad, Gobierno de España and by the CERCA Programme from the Generalitat de Catalunya. RN-L is supported by the research grant from the Generalitat de Catalunya (PERIS SLT/2381/2016/00099). The proteomics analyses were performed in the CRG/UPF Proteomics Unit which is part of the Proteored, PRB3 and is supported by grant PT17/0019, of the PE IDi 2013–2016, funded by ISCIII and ERDF
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer's disease cerebrospinal fluid

  • Lleó, Alberto
  • Chiva, Cristina
  • Sabidó Aguadé, Eduard, 1981-
  • Belbin, Olivia
A biomarker of synapse loss, an early event in Alzheimer's disease (AD) pathophysiology that precedes neuronal death and symptom onset, would be a much-needed prognostic biomarker. With direct access to the brain interstitial fluid, the cerebrospinal fluid (CSF) is a potential source of synapse-derived proteins. In this study, we aimed to identify and validate novel CSF biomarkers of synapse loss in AD. Discovery: Combining shotgun proteomics of the CSF with an exhaustive search of the literature and public databases, we identified 251 synaptic proteins, from which we selected 22 for further study. Verification: Twelve proteins were discarded because of poor detection by Selected Reaction Monitoring (SRM). We confirmed the specific expression of 9 of the remaining proteins (Calsynytenin-1, GluR2, GluR4, Neurexin-2A, Neurexin-3A, Neuroligin-2, Syntaxin-1B, Thy-1, Vamp-2) at the human synapse using Array Tomography microscopy and biochemical fractionation methods. Exploration: Using SRM, we monitored these 9 synaptic proteins (20 peptides) in a cohort of CSF from cognitively normal controls and subjects in the pre-clinical and clinical AD stages (n = 80). Compared with controls, peptides from 8 proteins were elevated 1.3 to 1.6-fold (p < 0.04) in prodromal AD patients. Validation: Elevated levels of a GluR4 peptide at the prodromal stage were replicated (1.3-fold, p = 0.04) in an independent cohort (n = 60). Moreover, 7 proteins were reduced at preclinical stage 1 (0.6 to 0.8-fold, p < 0.04), a finding that was replicated (0.7 to 0.8-fold, p < 0.05) for 6 proteins in a third cohort (n = 38). In a cross-cohort meta-analysis, 6 synaptic proteins (Calsyntenin-1, GluR4, Neurexin-2A, Neurexin-3A, Syntaxin-1B and Thy-1) were reduced 0.8-fold (p < 0.05) in preclinical AD, changes that precede clinical symptoms and CSF markers of neurodegeneration. Therefore, these proteins could have clinical value for assessing disease progression, especially in preclinical stages of AD., This work was supported by the following research grants: Fondos de Investigaciones Sanitarias (PI15/00058, PI14/01561, PI18/000327) from the “Fondo Europeo de Desarrollo Regional (FEDER)”, Unión Europea, “Una manera de hacer Europa” and the “Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Gobierno de España” (ISCIII). Additional funding came from the “Departament de Salut, Generalitat de Cataluña - Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016 –2020, 2017–2019” (SLT002/16/00408, 2017SGR547), “Programa 1 Enfermedad de Alzheimer y otras demencias degenerativas” from the Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), the “Fundació Bancaria La Caixa” (4560/6393) and “La Marató” organized by the television channel, TV3 (20142610). OB is supported by the Miguel Servet program (CP13/00091) from the ISCIII and FEDER. AB is supported by the Ministerio de Economia y Competitividad, Gobierno de España and FEDER (BFU2012-34398 and BFU2015-69717-P), by the Career Integration Grant from the European Union (ref. 304111, Marie Curie Actions), by the Ramón y Cajal Fellowship (ref. RYC-2011-08391) from the Ministerio de Economia y Competitividad, Gobierno de España and by the CERCA Programme from the Generalitat de Catalunya. RN-L is supported by the research grant from the Generalitat de Catalunya (PERIS SLT/2381/2016/00099). The proteomics analyses were performed in the CRG/UPF Proteomics Unit which is part of the Proteored, PRB3 and is supported by grant PT17/0019, of the PE IDi 2013–2016, funded by ISCIII and ERDF
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SynGAP splice variants display heterogeneous spatio-temporal expression and subcellular distribution in the developing mammalian brain

  • Gou Alsina, Gemma|||0000-0001-7438-2417
  • Roca-Fernandez, Adriana
  • Kilinc, Murat
  • Serrano, Elena|||0000-0001-8326-2775
  • Reig-Viader, Rita|||0000-0002-6893-6177
  • Araki, Yoichi
  • Huganir, Richard L.
  • Quintana Schmidt, Cristian de|||0000-0001-7825-4623
  • Rumbaugh, Gavin
  • Bayés, Àlex|||0000-0002-5265-6306
The SynGAP protein is a major regulator of synapse biology and neural circuit function. Genetic variants linked to epilepsy and intellectual disability disrupt synaptic function and neural excitability. SynGAP has been involved in multiple signaling pathways and can regulate small GTPases with very different roles. Yet, the molecular bases behind this pleiotropy are poorly understood. We hypothesize that different SynGAP isoforms will mediate different sets of functions and that deciphering their spatio-temporal expression and subcellular localization will accelerate understanding their multiple functions. Using isoform-specific antibodies recognizing SynGAP in mouse and human samples we found distinctive developmental expression patterns for all SynGAP isoforms in five mouse brain areas. Particularly noticeable was the delayed expression of SynGAP-α1 isoforms, which directly bind to postsynaptic density-95, in cortex and hippocampus during the first 2 weeks of postnatal development. Suggesting that during this period other isoforms would have a more prominent role. Furthermore, we observed subcellular localization differences between isoforms, particularly throughout postnatal development. Consistent with previous reports, SynGAP was enriched in the postsynaptic density in the mature forebrain. However, SynGAP was predominantly found in non-synaptic locations in a period of early postnatal development highly sensitive to SynGAP levels. While, α1 isoforms were always found enriched in the postsynaptic density, α2 isoforms changed from a non-synaptic to a mostly postsynaptic density localization with age and β isoforms were always found enriched in non-synaptic locations. The differential expression and subcellular distribution of SynGAP isoforms may contribute to isoform-specific regulation of small GTPases, explaining SynGAP pleiotropy. Syngap1 gene encodes for different synaptic Ras/Rap GTPase-activating (SynGAP) isoforms which are key for brain function. SynGAP C-termini splice variants show different spatio-temporal expression and subcellular localization in the developing mouse brain. This study reveals a non-synaptic and heterogenous role of SynGAP spliced variants. Depicted abundance differences only allow relative comparison within a given tissue (top panel), postnatal age (PND, middle panel), or subcellular distribution (bottom panel). Ctx, cortex; Hip, hippocampus; Str, striatum; OB, Olfactory Bulb; Crb, cerebellum and tSynGAP, total SynGAP.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

AMPA receptor auxiliary subunits emerged during early vertebrate evolution by neo/subfunctionalization of unrelated proteins

  • Ramos-Vicente, David|||0000-0002-2730-0850
  • Bayés, Àlex|||0000-0002-5265-6306
In mammalian synapses, the function of ionotropic glutamate receptors is critically modulated by auxiliary subunits. Most of these specifically regulate the synaptic localization and electrophysiological properties of AMPA-type glutamate receptors (AMPARs). Here, we comprehensively investigated the animal evolution of the protein families that contain AMPAR auxiliary subunits (ARASs). We observed that, on average, vertebrates have four times more ARASs than other animal species. We also demonstrated that ARASs belong to four unrelated protein families: CACNG-GSG1, cornichon, shisa and Dispanin C. Our study demonstrates that, despite the ancient origin of these four protein families, the majority of ARASs emerged during vertebrate evolution by independent but convergent processes of neo/subfunctionalization that resulted in the multiple ARASs found in present vertebrate genomes. Importantly, although AMPARs appeared and diversified in the ancestor of bilateral animals, the ARAS expansion did not occur until much later, in early vertebrate evolution. We propose that the surge in ARASs and consequent increase in AMPAR functionalities, contributed to the increased complexity of vertebrate brains and cognitive functions.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization of the TLR Family in Branchiostoma lanceolatum and Discovery of a Novel TLR22-Like Involved in dsRNA Recognition in Amphioxus

  • Ji, Jie|||0000-0002-3087-8370
  • Ramos-Vicente, David|||0000-0002-2730-0850
  • Navas-Pérez, Enrique
  • Herrera-Úbeda, Carlos
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • García-Fernández, Jordi
  • Escrivà, Hector
  • Bayés, Àlex|||0000-0002-5265-6306
  • Roher Armentia, Nerea|||0000-0002-6659-4038
Toll-like receptors (TLRs) are important for raising innate immune responses in both invertebrates and vertebrates. Amphioxus belongs to an ancient chordate lineage which shares key features with vertebrates. The genomic research on TLR genes in Branchiostoma floridae and Branchiostoma belcheri reveals the expansion of TLRs in amphioxus. However, the repertoire of TLRs in Branchiostoma lanceolatum has not been studied and the functionality of amphioxus TLRs has not been reported. We have identified from transcriptomic data 30 new putative TLRs in B. lanceolatum and all of them are transcribed in adult amphioxus. Phylogenetic analysis showed that the repertoire of TLRs consists of both non-vertebrate and vertebrate-like TLRs. It also indicated a lineage-specific expansion in orthologous clusters of the vertebrate TLR11 family. We did not detect any representatives of the vertebrate TLR1, TLR3, TLR4, TLR5 and TLR7 families. To gain insight into these TLRs, we studied in depth a particular TLR highly similar to a B. belcheri gene annotated as bbtTLR1. The phylogenetic analysis of this novel BlTLR showed that it clusters with the vertebrate TLR11 family and it might be more related to TLR13 subfamily according to similar domain architecture. Transient and stable expression in HEK293 cells showed that the BlTLR localizes on the plasma membrane, but it did not respond to the most common mammalian TLR ligands. However, when the ectodomain of BlTLR is fused to the TIR domain of human TLR2, the chimeric protein could indeed induce NF-κB transactivation in response to the viral ligand Poly I:C, also indicating that in amphioxus, specific accessory proteins are needed for downstream activation. Based on the phylogenetic, subcellular localization and functional analysis, we propose that the novel BlTLR might be classified as an antiviral receptor sharing at least partly the functions performed by vertebrate TLR22. TLR22 is thought to be viral teleost-specific TLR but here we demonstrate that teleosts and amphioxus TLR22-like probably shared a common ancestor. Additional functional studies with other lancelet TLR genes will enrich our understanding of the immune response in amphioxus and will provide a unique perspective on the evolution of the immune system.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Metazoan evolution of glutamate receptors reveals unreported phylogenetic groups and divergent lineage-specific events

  • Ramos-Vicente, David|||0000-0002-2730-0850
  • Ji, Jie|||0000-0002-3087-8370
  • Gratacòs-Batlle, Esther
  • Gou Alsina, Gemma|||0000-0001-7438-2417
  • Reig-Viader, Rita|||0000-0002-6893-6177
  • Luís, Javier
  • Burguera, Demian
  • Navas-Pérez, Enrique
  • García-Fernández, Jordi
  • Fuentes-Prior, Pablo|||0000-0002-6618-3204
  • Escrivà, Hector
  • Roher Armentia, Nerea|||0000-0002-6659-4038
  • Soto, David
  • Bayés, Àlex|||0000-0002-5265-6306
Glutamate receptors are divided in two unrelated families: ionotropic (iGluR), driving synaptic transmission, and metabotropic (mGluR), which modulate synaptic strength. The present classification of GluRs is based on vertebrate proteins and has remained unchanged for over two decades. Here we report an exhaustive phylogenetic study of GluRs in metazoans. Importantly, we demonstrate that GluRs have followed different evolutionary histories in separated animal lineages. Our analysis reveals that the present organization of iGluRs into six classes does not capture the full complexity of their evolution. Instead, we propose an organization into four subfamilies and ten classes, four of which have never been previously described. Furthermore, we report a sister class to mGluR classes I-III, class IV. We show that many unreported proteins are expressed in the nervous system, and that new Epsilon receptors form functional ligand-gated ion channels. We propose an updated classification of glutamate receptors that includes our findings. Nerve cells or neurons communicate with each other by releasing specific molecules in the gap between them, the synapses. The sending neuron passes on messages through packets of chemicals called neurotransmitters, which are picked up by the receiving cell with the help of receptors on its surface. Neurons use different neurotransmitters to send different messages, but one of the most common ones is glutamate. There are two families of glutamate receptors: ionotropic receptors, which can open or close ion channels in response to neurotransmitters and control the transmission of a signal, and metabotropic receptors, which are linked to a specific protein and control the strength of signal. Our understanding of these two receptor families comes from animals with backbones, known as vertebrates. But the receptors themselves are ancient. We can trace the first family back as far as bacteria and the second back to single-celled organisms like amoebas. Vertebrates have six classes of ionotropic and three classes of metabotropic glutamate receptor. But other multi-celled animals also have these receptors, so this picture may not be complete. Here, Ramos-Vicente et al. mapped all major lineages of animals to reveal the evolutionary history of these receptors to find out if the receptor families became more complicated as brain power increased. The results showed that the glutamate receptors found in vertebrates are only a fraction of all the types that exist. In fact, before present-day animal groups emerged, the part of the genome that holds the ionotropic receptor genes duplicated three times. This formed four receptor subfamilies, and our ancestors had all of them. Across the animal kingdom, there are ten, not six, classes of ionotropic receptors and there is an extra class of metabotropic receptors. But only two subfamilies of ionotropic and three out of four metabotropic receptor classes are still present in vertebrates today. The current classification of glutamate receptors centers around vertebrates, ignoring other animals. But this new data could change that. A better knowledge of these new receptors could aid neuroscientists in better understanding the nervous system. And, using this technique to study other families of proteins could reveal more missing links in evolution.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Synaptic proteomics as a means to identify the molecular basis of mental illness, Are we getting there?

  • Reig-Viader, Rita|||0000-0002-6893-6177
  • Sindreu, Carlos|||0000-0001-6730-8278
  • Bayés, Àlex|||0000-0002-5265-6306
Synapses are centrally involved in many brain disorders, particularly in psychiatric and neurodevelopmental ones. However, our current understanding of the proteomic alterations affecting synaptic performance in the majority of mental illnesses is limited. As a result, novel pharmacotherapies with improved neurological efficacy have been scarce over the past decades. The main goal of synaptic proteomics in the context of mental illnesses is to identify dysregulated molecular mechanisms underlying these conditions. Here we reviewed and performed a meta-analysis of previous neuroproteomic research to identify proteins that may be consistently dysregulated in one or several mental disorders. Notably, we found very few proteins reproducibly altered among independent experiments for any given condition or between conditions, indicating that we are still far from identifying key pathophysiological mechanisms of mental illness. We suggest that future research in the field will require higher levels of standardization and larger-scale experiments to address the challenge posed by biological and methodological variability. We strongly believe that more resources should be placed in this field as the need to identify the molecular roots of mental illnesses is highly pressing.